Why Regeneron Is Halting Coronavirus Antibody Cocktail Study Enrollment In Patients With Severe Cases – Benzinga

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) faced a setback Friday in a trial evaluating its antibody cocktail REGN-COV2 in hospitalized COVID-19 patients.
What Happened: An independent data monitoring committee recommended that further enrollment of patients requiring high-flow oxygen or mechanical ventilation be placed on hold, citing a potential safety signal and an unfavorable risk-benefit profile at this time, Regeneron said Friday. 
The committee recommended continuing the enrollment of hospitalized…

Click here to view the original article.